Skip to main content

Search

Show all results for

Home

Person

Iraklis Kourtis

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (6)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Engineering antigens for in situ erythrocyte binding induces T-cell deletion

Jeffrey Alan Hubbell, Stephane Kontos, Iraklis Kourtis, Karen Dane

Antigens derived from apoptotic cell debris can drive clonal T-cell deletion or anergy, and antigens chemically coupled ex vivo to apoptotic cell surfaces have been shown correspondingly to induce tolerance on infusion. Reasoning that a large number of ery ...

Natl Acad Sciences2013

Ccr7 ligand delivery and co-delivery in immunotherapy

Jeffrey Alan Hubbell, Melody Swartz, Alice Anna Tomei, Iraklis Kourtis

Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described. ...

2017

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

Jeffrey Alan Hubbell, Melody Swartz, Laura Jeanbart, Iraklis Kourtis

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress effector T cell responses and can reduce the efficacy of cancer immunotherapies. We previously showed that ultra-small polymer nanoparticles eff ...

Springer2015